Michael Grissinger

Michael Grissinger currently serves as Chair of the Board of Directors for AnaCardio and NephroDI Therapeutics, Inc., while also holding board member positions for Aprea Therapeutics, Envisagenics, Akari Therapeutics, and previously for Atriva Therapeutics and resTORbio. Prior to these roles, Michael Grissinger was a Senior Advisor at Cerberus Capital Management and spent over two decades at Johnson & Johnson, culminating in various Vice President positions where significant transactions including the $30 billion acquisition of Actelion and several key pharma deals were executed. Michael Grissinger holds an M.B.A. in Finance from the Fox School of Business at Temple University and a Bachelor of Science in Chemistry from Juniata College.